Dr. Miri Ben-Ami, Vice President for Clinical Development and Regulatory Affairs with Aposense, Ltd., discusses the "bench to clinic" applications of Apoptosis Imaging using ML-10 PET in the Emerging Technologies Session at the 2010 SNM Annual Meeting. This lecture reviews the function of apoptosis and how it can be used to evaluate treatment effects for different types of disease. Dr. Ben-Ami also reviews the completed trial results of the ML-10 tracer and current and proposed trial information of ML-10. ML10 is an investigational drug and not currently approved by the FDA. IBA Molecular North America, Inc. (and its affiliates) have a business relationship with Aposense for ML-10 PET.
Very convincing and encouraging. Seems like there's a lot of potential in this area. We should watch this space. Excellent delivery by the speaker.
dani5734 1 year ago